Log in

Relevant bibliographies by topics / 90-90-90 Target / Journal articles

To see the other types of publications on this topic, follow the link: 90-90-90 Target.

Journal articles on the topic '90-90-90 Target'

Author: Grafiati

Published: 5 June 2025

Last updated: 24 June 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic '90-90-90 Target.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Wainberg, Mark A., Mark W. Hull, Pierre-Marie Girard, and Julio S. G. Montaner. "Achieving the 90–90–90 target: incentives for HIV testing." Lancet Infectious Diseases 16, no. 11 (2016): 1215–16. http://dx.doi.org/10.1016/s1473-3099(16)30383-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Celum, Connie, and Ruanne Barnabas. "Reaching the 90-90-90 target: lessons from HIV self-testing." Lancet HIV 6, no. 2 (2019): e68-e69. http://dx.doi.org/10.1016/s2352-3018(18)30289-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Iwuji, Collins, and Marie-Louise Newell. "HIV testing: the ‘front door’ to the UNAIDS 90–90–90 target." Public Health Action 7, no. 2 (2017): 79. http://dx.doi.org/10.5588/ijtld.17.0046.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Mete, Bilgul, Alper Gunduz, Sibel Bolukcu, et al. "HIV care in Istanbul, Turkey: How far is it from the UNAIDS 90–90–90 targets?" International Journal of STD & AIDS 30, no. 13 (2019): 1298–303. http://dx.doi.org/10.1177/0956462419866342.

Full text

Abstract:

The prevalence of human immunodeficiency virus (HIV) infection is low but it is steadily increasing in Turkey. In the current study, we aimed to assess the status of HIV infection management with the proposed 90–90–90 targets in a large HIV cohort in Istanbul, Turkey. The cohort included 2382 patients (2082 male, 300 female, mean age was 36.3 ± 11.3 years). Mean CD4 cell count was 399 cells/mm3 and HIV-RNA level was 576,235 copies/ml. According to the modeling by the Modeling tool of European Center for Diseases Control Software, 72 and 74% of all HIV patients had been diagnosed in 2016 and 2017, respectively (the first target). Among 2382 patients, 2191 (92%) were on antiretroviral therapy (the second target). The third target of virally suppressing those on treatment was achieved among 70.2% of the patients. The current study suggests that both the fraction of those living with undiagnosed HIV and the proportion of those on treatment who are virally suppressed should be targeted to sustain optimal HIV care. Efforts should continue to surpass the targets of 90–90–90.

APA, Harvard, Vancouver, ISO, and other styles

5

Kumbasar, Hayat. "How Does the CovÄ±d-19 PandemÄ±c Affect the Target 90-90-90?" Current HIV Research 19, no. 2 (2021): 103–5. http://dx.doi.org/10.2174/18734251mtexkodui1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Almunif, S., M. Alshamrani, A. El-Saeed, and E. AlMazroa. "Achieving the United Nations AIDS (UNAIDS) 90-90-90 Target; A Single Center Experience." Journal of Infection and Public Health 12, no. 1 (2019): 110. http://dx.doi.org/10.1016/j.jiph.2018.10.022.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Iwuji, Collins, and Marie-Louise Newell. "Towards control of the global HIV epidemic: Addressing the middle-90 challenge in the UNAIDS 90–90–90 target." PLOS Medicine 14, no. 5 (2017): e1002293. http://dx.doi.org/10.1371/journal.pmed.1002293.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Bain, Luchuo Engelbert, Clovis Nkoke, and Jean Jacques N. Noubiap. "UNAIDS 90–90–90 targets to end the AIDS epidemic by 2020 are not realistic: comment on “Can the UNAIDS 90–90–90 target be achieved? A systematic analysis of national HIV treatment cascades”." BMJ Global Health 2, no. 2 (2017): e000227. http://dx.doi.org/10.1136/bmjgh-2016-000227.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Schiaroli, Elisabetta. "The PARTIAL ACHIEVEMENT OF THE 90-90-90 UNAIDS TARGET IN A COHORT OF HIV INFECTED PATIENTS FROM CENTRAL ITALY." Mediterranean Journal of Hematology and Infectious Diseases 12, no. 1 (2020): e2020017. http://dx.doi.org/10.4084/mjhid.2020.017.

Full text

Abstract:

Despite progress in the prevention and treatment of HIV, persistent issues concerning the evaluation of continuum in care from the serological diagnosis to virologic success remain. Considering the UNAIDS target 90-90-90 for 2020 for treatment and viral suppression of people living with HIV (PLVH), our purpose was to verify if, starting from diagnosis, the viral suppression rate of our cohort of new PLWH satisfied the above targets. The aim of this retrospective study was to compare 2005-2017 data collected at the Perugia Infectious Diseases Clinic with the 2020 UNAIDS 90 targets and to identify risk factors that could be associated with failure to reach these targets. Methods: We included all patients aged ≥15 undergoing HIV test at our clinic between January 2005 and December 2017. We evaluated the unclaimed tests, linkage to care, retention in ART and the viral suppression at 1 and 2 years from starting ART. Data were analyzed between Italians and foreigners. Results: We observed 592 new diagnoses for HIV infection: 61.4% on Italian-natives, 38.5% on foreigners. Considering the continuum of care from diagnosis, 88 (15%) PLWHIV were lost to engagement in care: 55 (9.2%) patients didn’t withdraw the test and 33 (5.5%) didn’t link to care. An antiretroviral treatment was started only on 78.8% of the new diagnoses (467/592) and a viral suppression was obtained at 2 years on 82% of PLWH who had started ART (383/467) namely only 64.7% of the new diagnoses instead of the hoped-for 81% of the UNAIDS target. We found no significant differences between Italians and foreigners Conclusions UNAIDS goal was very far to be reached. The main challenges were unreturned tests as well as the retention in ART. Rapid tests for a test-treat strategy and frequent phone communications in the first ART years could facilitate UNAIDS target achievement.

APA, Harvard, Vancouver, ISO, and other styles

10

Levi, Jacob, Alice Raymond, Anton Pozniak, Pietro Vernazza, Philipp Kohler, and Andrew Hill. "Can the UNAIDS 90-90-90 target be achieved? A systematic analysis of national HIV treatment cascades." BMJ Global Health 1, no. 2 (2016): e000010. http://dx.doi.org/10.1136/bmjgh-2015-000010.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Porter, Kholoud, Annabelle Gourlay, Kathy Attawell, et al. "Substantial Heterogeneity in Progress Toward Reaching the 90-90-90 HIV Target in the WHO European Region." JAIDS Journal of Acquired Immune Deficiency Syndromes 79, no. 1 (2018): 28–37. http://dx.doi.org/10.1097/qai.0000000000001761.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Essajee, Shaffiq, Lara Vojnov, Martina Penazzato, et al. "Reducing mortality in HIV-infected infants and achieving the 90-90-90 target through innovative diagnosis approaches." Journal of the International AIDS Society 18 (December 2015): 20299. http://dx.doi.org/10.7448/ias.18.7.20299.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Wirawan, Dewa Nyoman. "Stigma and discrimination: Barrier for ending AIDS by 2030 and achieving the 90-90-90 targets by 2020." Public Health and Preventive Medicine Archive 7, no. 1 (2019): 1. http://dx.doi.org/10.15562/phpma.v7i1.206.

Full text

Abstract:

The Joint United Nations Programme on HIV-AIDS (UNAIDS) put forward an ambitious vision of “three zero” which consisted of zero new HIV infections, zero discrimination and zero AIDS-related deaths. In other words, it is envisaged there will be no new HIV infections, no more discrimination towards people living with HIV and no more AIDS-related deaths. UNAIDS also set the target of “ending AIDS” as a public health threat by 2030. In order to end the HIV epidemic by 2030, in 2014 UNAIDS established a fast tract strategy namely "90-90-90" which means by 2020, 90% of all people living with HIV will know their HIV status, 90% of all people with diagnosed HIV infection will receive sustained access to antiretroviral therapy (ART) and 90% of all people receiving antiretroviral therapy will achieve viral suppression. If this target of "90-90-90" is achieved, it is estimated that by 2020 at least 73% of all people living with HIV worldwide will experience viral suppression; further modeling suggests that if this target is achieved this will bring about the “end of AIDS” by 2030.

APA, Harvard, Vancouver, ISO, and other styles

14

Granich, Reuben, and Somya Gupta. "Progress towards the 90-90-90 target: review of status and methodology of reported National HIV Care Continua." Journal of Virus Eradication 4 (May 2018): 24. http://dx.doi.org/10.1016/s2055-6640(20)30392-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Sidibé, Michel, Luiz Loures, and Badara Samb. "The UNAIDS 90-90-90 target: a clear choice for ending AIDS and for sustainable health and development." Journal of the International AIDS Society 19, no. 1 (2016): 21133. http://dx.doi.org/10.7448/ias.19.1.21133.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Scott, Nick, Mark Stoové, Sherrie L. Kelly, David P. Wilson, and Margaret E. Hellard. "Achieving 90-90-90 Human Immunodeficiency Virus (HIV) Targets Will Not Be Enough to Achieve the HIV Incidence Reduction Target in Australia." Clinical Infectious Diseases 66, no. 7 (2017): 1019–23. http://dx.doi.org/10.1093/cid/cix939.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Bhattacharjee, Chiranjib, and Lokesh Deb. "The Role of Heat Shock Protein -90 (HSP-90) in Inflammatory Disorders." Current Chemical Biology 14, no. 1 (2020): 30–37. http://dx.doi.org/10.2174/2212796814666200122114833.

Full text

Abstract:

In human cells, Heat Shock Protein-90 (HSP-90) is present in the cytosol, nucleoplasm, endoplasmic reticulum, and mitochondria. The eukaryotic HSP-90 is multifunctionary and essential for cell viability, signal transduction, cell-cycle control as well as transcriptional regulation. The intracellular environment does not restrict HSP-90. It has a vital role in all types of inflammatory disorders, including cancer, autoimmune diseases, infectious inflammatory conditions. Hence, pharmacological inhibition of HSP-90 is currently a choice of therapeutic target for the treatment of autoimmune diseases, cancer, and infectious diseases. Based on the biology of HSP-90, several COOH-terminal ATPase sites of HSP-90, NH2-terminal ATPase sites of HSP-90, and Histone deacetylase inhibitors are evaluated and classified under various groups. For the treatment of different inflammatory disorders, HSP-90 identified as a promising therapeutic target. The present review may guide researchers for evaluating the HSP-90 targeted pathway as a useful therapeutic target for inflammatory diseases, including cancers.

APA, Harvard, Vancouver, ISO, and other styles

18

Estill, Janne, Kimberly Marsh, Christine Autenrieth, and Nathan Ford. "How to achieve the global 90-90-90 target by 2020 in sub-Saharan Africa? A mathematical modelling study." Tropical Medicine & International Health 23, no. 11 (2018): 1223–30. http://dx.doi.org/10.1111/tmi.13145.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Rentsch, Christopher T., Georges Reniers, Richard Machemba, et al. "Non-disclosure of HIV testing history in population-based surveys: implications for estimating a UNAIDS 90-90-90 target." Global Health Action 11, no. 1 (2018): 1553470. http://dx.doi.org/10.1080/16549716.2018.1553470.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Junior, Cecilio Argolo, Mírian Rique De Souza Brito Dias, Cristina Maria De Souza Brito Dias, and Isabelle Diniz Cerqueira Leite. "COMPROMETIMENTO DA META 90-90-90: IMPACTO NA PREVENÇÃO, DIAGNÓSTICO E TRATAMENTO DE AIDS DURANTE A PANDEMIA DE CORONAVÍRUS-2019 / TARGET COMMITMENT 90-90-90: IMPACT ON AIDS PREVENTION, DIAGNOSIS, AND TREATMENT DURING CORONAVIRUS PANDEMIC-2019." Brazilian Journal of Development 7, no. 2 (2021): 16834–48. http://dx.doi.org/10.34117/bjdv7n2-350.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Bajunirwe, Francis, Flora Tumwebaze, Denis Akakimpa, Cissy Kityo, Peter Mugyenyi, and George Abongomera. "Towards 90-90-90 Target: Factors Influencing Availability, Access, and Utilization of HIV Services—A Qualitative Study in 19 Ugandan Districts." BioMed Research International 2018 (2018): 1–10. http://dx.doi.org/10.1155/2018/9619684.

Full text

Abstract:

Background. UNAIDS has set a new target 90-90-90 by 2020. To achieve this target, current programs need to address challenges that limit access, availability, and utilization of HIV testing and treatment services. Therefore, the aim of this study was to identify the barriers that influence access, availability, and utilization of HIV services in rural Uganda within the setting of a large donor funded program. Methods. We conducted key informant interviews with stakeholders at the district level, staff of existing HIV/AIDS projects, and health facilities in 19 districts. Data were also collected from focus group discussions comprised of clients presenting for HIV care and treatment. Data were transcribed and analyzed using content analysis. Results. Barriers identified were as follows: (1) drug shortages including antiretroviral drugs at health facilities. Some patients were afraid to start ART because of worrying about shortages; (2) distance and (3) staffing shortages; (4) stigma persistence; (5) lack of social and economic support initiatives that enhance retention in treatment. Conclusions. In conclusion, our study has identified several factors that influence access, availability, and utilization of HIV services. Programs need to address drug and staff shortages, HIV stigma, and long distances to health facilities to broaden access and utilization in order to realize the UNAIDS target.

APA, Harvard, Vancouver, ISO, and other styles

22

Ssekalembe, Geofrey, Muhammad Atoillah Isfandiari, and Hendick Suprianto. "Current Status Towards 90-90-90 UNAIDS Target and Factors Associated with HIV Viral Load Suppression in Kediri City, Indonesia." HIV/AIDS - Research and Palliative Care Volume 12 (January 2020): 47–57. http://dx.doi.org/10.2147/hiv.s231173.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Wright, Chadwick L., Jun Zhang, Michael F. Tweedle, Michael V. Knopp, and Nathan C. Hall. "Theranostic Imaging of Yttrium-90." BioMed Research International 2015 (2015): 1–11. http://dx.doi.org/10.1155/2015/481279.

Full text

Abstract:

This paper overviews Yttrium-90 (90Y) as a theranostic and nuclear medicine imaging of90Y radioactivity with bremsstrahlung imaging and positron emission tomography. In addition, detection and optical imaging of90Y radioactivity using Cerenkov luminescence will also be reviewed. Methods and approaches for qualitative and quantitative90Y imaging will be briefly discussed. Although challenges remain for90Y imaging, continued clinical demand for predictive imaging response assessment and target/nontarget dosimetry will drive research and technical innovation to provide greater clinical utility of90Y as a theranostic agent.

APA, Harvard, Vancouver, ISO, and other styles

24

Maheu-Giroux, Mathieu, Juan F. Vesga, Souleymane Diabaté, et al. "Population-level impact of an accelerated HIV response plan to reach the UNAIDS 90-90-90 target in Côte d’Ivoire: Insights from mathematical modeling." PLOS Medicine 14, no. 6 (2017): e1002321. http://dx.doi.org/10.1371/journal.pmed.1002321.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Lakhani, A. D., R. W. Morris, M. Morgan, C. Dale, and M. S. Vaile. "Measles immunisation: feasibility of a 90% target uptake." Archives of Disease in Childhood 62, no. 12 (1987): 1209–14. http://dx.doi.org/10.1136/adc.62.12.1209.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

CULLINAN, S., and L. WHITESELL. "Heat Shock Protein 90: A Unique Chemotherapeutic Target." Seminars in Oncology 33, no. 4 (2006): 457–65. http://dx.doi.org/10.1053/j.seminoncol.2006.04.001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Jacob, H. "90 Localisation of the boost target: Minimal requirements." Radiotherapy and Oncology 60 (January 2001): S26. http://dx.doi.org/10.1016/s0167-8140(01)80096-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Lombe, Dorothy, Susan Msadabwe, Mbaita Maka, et al. "Zambia cervical cancer control program resource mapping – Leveraging support to achieve the 90-70-90 elimination target." Journal of Cancer Policy 28 (June 2021): 100281. http://dx.doi.org/10.1016/j.jcpo.2021.100281.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Chipanta, David, Silas Amo-Agyei, Danielle Giovenco, Janne Estill, and Olivia Keiser. "Socioeconomic inequalities in the 90–90–90 target, among people living with HIV in 12 sub-Saharan African countries — Implications for achieving the 95–95–95 target — Analysis of population-based surveys." eClinicalMedicine 53 (November 2022): 101652. http://dx.doi.org/10.1016/j.eclinm.2022.101652.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Euvrard, J., T. Schulz, K. Hilderbrand, et al. "How accurately do routinely reported HIV viral load suppression proportions reflect progress towards the 90-90-90 target in the population on antiretroviral treatment in Khayelitsha, South Africa?" South African Medical Journal 109, no. 3 (2019): 174. http://dx.doi.org/10.7196/samj.2019.v109i3.13456.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Arslan, Nuri, Mustafa Emi, Engin Alagöz, et al. "Selective intraarterial radionuclide therapy with yttrium-90 (Y-90) microspheres for hepatic neuroendocrine metastases: Initial experience at a single center." Vojnosanitetski pregled 68, no. 4 (2011): 341–48. http://dx.doi.org/10.2298/vsp1104341a.

Full text

Abstract:

Background/Aim. Selective intraarterial radionuclide therapy (SIRT) with Yttrium-90 (Y-90) microspheres is also known as radioembolization and delivers high doses of radiation to hepatic tumors with minimum healthy liver exposure. The aim of this study was to present our preliminary experience in the role of liver directed radiotherapy with Y-90 microspheres for the treatment of unresectable hepatic metastases from neuroendocrine tumors (NET). Methods. The results of SIRT in 10 patients (5 males, 5 females; mean age 48.7 years; age range 24-73 years) with metastatic liver disease from NETs during the period from April 2008 through August 2010 were reviewed. All patients had meticulous pre- and post-imaging studies as a part of their work-up procedure, as well as serologic tests of liver function to determine the extent of liver function damage. The patients who were eligible for SIRT had pretreatment visceral angiography to define and occlude non-target arteries. Results. The mean ? SD administered SIR-Spheres? activity was 1.49 ? 0.42 GBq (range 0.72-2.21 GBq) in all the patients. These treatments delivered a dose of 99.73 ? 66.36 Gy (range 49- 420.8 Gy) to the target tumors. The estimated dose to the lungs and normal liver was 4.45 ? 1.95 Gy (range 2.4-8.5 Gy) and 26.73 ? 14.19 Gy (range 5-58.9 Gy), respectively. Overall response rate of 90% and patient tolerance was satisfactory for most patients. Conclusion. From our limited experience, we can conclude that SIRT with Y-90 microspheres is a safe and efficacious treatment option for patients with liver metastasis of NET without any serious side effects.

APA, Harvard, Vancouver, ISO, and other styles

32

Zhang, Song, Jiaqing Shi, Xun Li, Xiaodong Yu, Chengwen Tan, and Zhihua Nie. "Texture Evolution of High-purity Tantalum during 90°Clock Rolling." Journal of Physics: Conference Series 2845, no. 1 (2024): 012036. http://dx.doi.org/10.1088/1742-6596/2845/1/012036.

Full text

Abstract:

Abstract When fabricating high-purity tantalum targets for the sputtering procedure of integrated circuit manufacturing, a through-thickness texture gradient can form in the rolled tantalum (Ta) plate. This texture gradient hinders the target sputtering performance, reducing chip reliability. This study investigated the texture evolution during the 90°clock rolling through experimental and simulation methods. Balancing the plane strain deformation with the surface shear strain deformation during fabrication and limiting the total rolling reduction to no more than 85% can weaken the through-thickness texture gradient in the Ta plate. A crystal plasticity finite element method (CPFEM) model was developed to simulate the 90°clock rolling procedure in the ABAQUS/Explicit software. The simulation and the experimental results are in agreement, with slight differences in texture type and intensity due to tantalum’s complex slip behaviors.

APA, Harvard, Vancouver, ISO, and other styles

33

Barginear, M., C. Van Poznak, N. Rosen, S. Modi, C. Hudis, and D. Budman. "The Heat Shock Protein 90 Chaperone Complex: An Evolving Therapeutic Target." Current Cancer Drug Targets 8, no. 6 (2008): 522–35. http://dx.doi.org/10.2174/156800908785699379.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Whitfield, J. P., and N. T. Porile. "Target residues from the interaction of copper with 90 MeV/nucleonLi6ions." Physical Review C 49, no. 1 (1994): 304–13. http://dx.doi.org/10.1103/physrevc.49.304.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Pallavi, Rani, Nainita Roy, Rishi Kumar Nageshan, et al. "Heat Shock Protein 90 as a Drug Target against Protozoan Infections." Journal of Biological Chemistry 285, no. 49 (2010): 37964–75. http://dx.doi.org/10.1074/jbc.m110.155317.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

ROCHANI, ANKIT K., CHANDAN MITHRA, MEETALI SINGH, and UTPAL TATU. "Heat shock protein 90 as a potential drug target against surra." Parasitology 141, no. 9 (2014): 1148–55. http://dx.doi.org/10.1017/s0031182014000845.

Full text

Abstract:

SUMMARYTrypanosomiasis is caused by Trypanosoma species which affect both human and animal populations and pose a major threat to developing countries. The incidence of animal trypanosomiasis is on the rise. Surra is a type of animal trypanosomiasis, caused by Trypanosoma evansi, and has been included in priority list B of significant diseases by the World Organization of Animal Health (OIE). Control of surra has been a challenge due to the lack of effective drugs and vaccines and emergence of resistance towards existing drugs. Our laboratory has previously implicated Heat shock protein 90 (Hsp90) from protozoan parasites as a potential drug target and successfully demonstrated efficacy of an Hsp90 inhibitor in cell culture as well as a pre-clinical mouse model of trypanosomiasis. This article explores the role of Hsp90 in the Trypanosoma life cycle and its potential as a drug target. It appears plausible that the repertoire of Hsp90 inhibitors available in academia and industry may have value for treatment of surra and other animal trypanosomiasis.

APA, Harvard, Vancouver, ISO, and other styles

37

Isaacs, Jennifer S., Wanping Xu, and Len Neckers. "Heat shock protein 90 as a molecular target for cancer therapeutics." Cancer Cell 3, no. 3 (2003): 213–17. http://dx.doi.org/10.1016/s1535-6108(03)00029-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Shirota, Tomoki, Hidenori Ojima, Nobuyoshi Hiraoka, et al. "Heat Shock Protein 90 Is a Potential Therapeutic Target in Cholangiocarcinoma." Molecular Cancer Therapeutics 14, no. 9 (2015): 1985–93. http://dx.doi.org/10.1158/1535-7163.mct-15-0069.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Jensen, Hans Henrik, Erik L. Mortensen, and Martin Lotz. "SCL-90-R Symptom Profiles and Outcome of Short-Term Psychodynamic Group Therapy." ISRN Psychiatry 2013 (April 27, 2013): 1–7. http://dx.doi.org/10.1155/2013/540134.

Full text

Abstract:

Background. Psychodynamic group psychotherapy may not be an optimal treatment for anxiety and agoraphobic symptoms. We explore remission of SCL-90-R Global Severity Index (GSI) and target symptoms in 39 sessions of psychodynamic group therapy. Methods. SCL-90-R “target symptom” profile and GSI remission according to Danish norms were identified in 239 patients and evaluated according to reliable and clinical significant change. Results. Four major groups of target symptom cases (depression, interpersonal sensitivity, anxiety, and phobic anxiety) covered 95.7% of the sample. As opposite to phobic anxiety and anxiety patients, patients with interpersonal sensitivity obtained overall the most optimal outcome. The phobic anxiety scale, social network support, and years of school education were independent predictors of GSI remission, and a low anxiety score and absence of phobic anxiety target symptoms were independent predictors of remission of target symptom pathology. Conclusions. The negative results as associated with the SCL-90-R phobic anxiety scale and the phobic anxiety target symptom group are largely in agreement with recent studies. In contrast, whatever the diagnoses, patients with interpersonal sensitivity target symptom may be especially suited for psychodynamic group therapy. The SCL-90-R subscales may allow for a more complex symptom-related differentiation of patients compared with both diagnoses and GSI symptom load.

APA, Harvard, Vancouver, ISO, and other styles

40

IMARISIO, Roberto, Paolo GIARDINA-PAPA, and Massimo SIRACUSA. "The new 1.3 L 90 PS diesel engine." Combustion Engines 122, no. 3 (2005): 22–31. http://dx.doi.org/10.19206/ce-117397.

Full text

Abstract:

After the start of mass production in April 2003 of a completely new Euro 4, 1.3 L, common rail Diesel engine, an upgraded variant has been recently developed, with power output increased from 70 to 90 PS and torque output increased from 180 to 200 N·m. To meet this target the combustion system has been deeply revised and common rail pressure increased from 1400 to 1600 bar, while maintaining the multiple injection feature already introduced on the 70 PS variant. Moreover, a variable geometry, small turbocharger has been specifically developed and the mechanical components upgraded to comply with an increased peak cylinder pressure from 140 to 160 bar. In order to comply with Euro 4 emission standards on critical applications with high load factors new control functions have been developed, in order to reduce the dispersion and the drift in durability, such as the lambda control based on an O2 sensor. In spite of Euro 4 emission compliance on most of the forecasted applications with conventional DOC after-treatment, a DPF version will be provided as well, adopting the maintenance free technology already applied on other engines with higher displacement. The 1.3 L SDE family is manufactured in Poland, in a plant located in Bielsko Biala, with an installed production capacity close to 700.000 engines per year.

APA, Harvard, Vancouver, ISO, and other styles

41

Kiewe, P., K. Jahnke, S. Maza, A. Korfel, D. L. Munz, and E. Thiel. "Yttrium-90-labeled ibritumomab tiuxetan for primary CNS lymphoma." Journal of Clinical Oncology 24, no. 18_suppl (2006): 11512. http://dx.doi.org/10.1200/jco.2006.24.18_suppl.11512.

Full text

Abstract:

11512 Background: Salvage treatment has not yet been established in primary CNS lymphoma (PCNSL). Here we report first results of an ongoing phase II study with a single treatment course of Y-90 anti-CD20 antibody ibritumomab tiuxetan in relapsed/resistant PCNSL. Methods: Eligibility criteria include histologically confirmed, recurrent PCNSL after at least one prior treatment, HIV negativity and adequate bone marrow and cardiac function. Primary endpoint is overall response, secondary endpoints are response duration, survival, and toxicity including late neurotoxicity. Treatment includes rituximab 250 mg/m2 on day -7 and day 0, followed by Y-90-ibritumomab tiuxetan 15 MBq/kg IV. Response evaluation by contrast-enhanced magnetic resonance imaging (MRI) and fluorodeoxyglucose positron emission tomography (FDG-PET) is scheduled before, one month and two months after treatment as well as every three months thereafter in responders. In two patients single photon emission computed tomography (SPECT) target imaging with gamma-emitting 111-Indium-ibritumomab tiuxetan was performed repeatedly. Results: To date, four patients have been enrolled. Complete response on MRI and decreased but still detectable FDG-uptake in PET was seen in one patient; the response duration was one month. In another patient uncertain complete response with minimal residual contrast enhancement lasting 12+ months was observed. Two patients had disease progression. One patient developed CTC grade 3 pneumonia during CTC grade 2 leukopenia, two patients had CTC grade 3 thrombocytopenia lasting up to 6 weeks. SPECT indicated target accumulation in the tumor starting 48 hours and still ongoing 7 days after injection of 111-Indium-ibritumomab tiuxetan. Conclusions: This is the first report on a successful treatment of PCNSL with Y-90-ibritumomab tiuxetan and penetration of a therapeutic antibody into PCNSL, warranting further investigation. No significant financial relationships to disclose.

APA, Harvard, Vancouver, ISO, and other styles

42

Fu, Xun, Jiang Liu, Xin Yan, Michael E. DiSanto, and Xinhua Zhang. "Heat Shock Protein 70 and 90 Family in Prostate Cancer." Life 12, no. 10 (2022): 1489. http://dx.doi.org/10.3390/life12101489.

Full text

Abstract:

Prostate cancer (PCa) is the second most frequent cancer that affects aging men worldwide. However, its exact pathogenesis has not been fully elucidated. The heat shock protein (HSP) family has cell-protective properties that may promote tumor growth and protect cancer cells from death. On a cellular level, HSP molecules have a strong relationship with multiple important biological processes, such as cell differentiation, epithelial–mesenchymal transition (EMT), and fibrosis. Because of the facilitation of HSP family molecules on tumorigenesis, a number of agents and inhibitors are being developed with potent antitumor effects whose target site is the critical structure of HSP molecules. Among all target molecules, HSP70 family and HSP90 are two groups that have been well studied, and therefore, the development of their inhibitors makes great progress. Only a small number of agents, however, have been clinically tested in recruited patients. As a result, more clinical studies are warranted for the establishment of the relationship between the HSP70 family, alongside the HSP90 molecule, and prostate cancer treatment.

APA, Harvard, Vancouver, ISO, and other styles

43

Dabravolski, Siarhei A., Vasily N. Sukhorukov, Vladislav A. Kalmykov, Nikolay A. Orekhov, Andrey V. Grechko, and Alexander N. Orekhov. "Heat Shock Protein 90 as Therapeutic Target for CVDs and Heart Ageing." International Journal of Molecular Sciences 23, no. 2 (2022): 649. http://dx.doi.org/10.3390/ijms23020649.

Full text

Abstract:

Cardiovascular diseases (CVDs) are the leading cause of death globally, representing approximately 32% of all deaths worldwide. Molecular chaperones are involved in heart protection against stresses and age-mediated accumulation of toxic misfolded proteins by regulation of the protein synthesis/degradation balance and refolding of misfolded proteins, thus supporting the high metabolic demand of the heart cells. Heat shock protein 90 (HSP90) is one of the main cardioprotective chaperones, represented by cytosolic HSP90a and HSP90b, mitochondrial TRAP1 and ER-localised Grp94 isoforms. Currently, the main way to study the functional role of HSPs is the application of HSP inhibitors, which could have a different way of action. In this review, we discussed the recently investigated role of HSP90 proteins in cardioprotection, atherosclerosis, CVDs development and the involvements of HSP90 clients in the activation of different molecular pathways and signalling mechanisms, related to heart ageing.

APA, Harvard, Vancouver, ISO, and other styles

44

Folkersen, Lasse, Stefan Gustafsson, Qin Wang, et al. "Genomic and drug target evaluation of 90 cardiovascular proteins in 30,931 individuals." Nature Metabolism 2, no. 10 (2020): 1135–48. http://dx.doi.org/10.1038/s42255-020-00287-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Neckers, Len. "Heat Shock Protein 90 Is a Rational Molecular Target in Breast Cancer." Breast Disease 15, no. 1 (2002): 53–60. http://dx.doi.org/10.3233/bd-2002-15106.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Banerji, Udai. "Heat Shock Protein 90 as a Drug Target: Some Like It Hot." Clinical Cancer Research 15, no. 1 (2008): 9–14. http://dx.doi.org/10.1158/1078-0432.ccr-08-0132.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Yamada-Kanazawa, S., I. Kajihara, S. Fukushima, et al. "463 Heat shock protein 90 is a novel therapeutic target for angiosarcoma." Journal of Investigative Dermatology 136, no. 9 (2016): S239. http://dx.doi.org/10.1016/j.jid.2016.06.485.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Gulla, Aiste, Michael Chun, Wei Qiu, and Kestutis Strupas. "Target structure in pancreatic ductal adenocarcinoma: changes in heat shock protein 90." Pancreatology 23 (November 2023): e150-e151. http://dx.doi.org/10.1016/j.pan.2023.06.786.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Wang, Y., and S. R. McAlpine. "C-terminal heat shock protein 90 modulators produce desirable oncogenic properties." Organic & Biomolecular Chemistry 13, no. 16 (2015): 4627–31. http://dx.doi.org/10.1039/c5ob00044k.

Full text

Abstract:

The cellular protection mechanism, the heat shock response, is only activated by classical heat shock 90 inhibitors (Hsp90) that “target” the N-terminus of the protein, but not by those that modulate the C-terminus.

APA, Harvard, Vancouver, ISO, and other styles

50

Gupta, Somya, and Reuben Granich. "National HIV Care Continua for Key Populations." Journal of the International Association of Providers of AIDS Care (JIAPAC) 16, no. 2 (2017): 125–32. http://dx.doi.org/10.1177/2325957416686195.

Full text

Abstract:

We reviewed published national HIV care continua for men who have sex with men (MSM), people who inject drugs (PWID), and female sex workers (FSWs) to track progress toward the 90-90-90 target. We searched the Internet, PubMed, surveillance reports, United Nations Programme on HIV/AIDS country reports, US President’s Emergency Plan for AIDS Relief country/regional operational plans, and conference abstracts for the continua and graded them on quality. We found 12 continua for MSM, 7 for PWID, and 5 for FSW from 12 countries. HIV diagnosis, antiretroviral therapy coverage, and viral suppression varied between (1) 5% and 85%, 2% and 73%, and 1% and 72%, respectively for MSM; (2) 54% and 96%, 14% and 80%, and 8% and 68%, respectively for PWID; and (3) 27% and 63%, 8% and 16%, and 2% and 14%, respectively for FSW. Two countries, using data from national cohorts, were high quality. There are limited key population continua in the public domain. Of the few available, none have achieved 90-90-90. Improved monitoring and evaluation of key population continua is necessary to achieve the 90-90-90 target.

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!